Week Ending June 27, 2022

Lung cancer patients treated with immune checkpoint inhibitors can be safely vaccinated against COVID-19, study says
“Cancer patients have received priority status to receive COVID-19 vaccinations but there is limited data regarding the safety and efficacy of the vaccines for patients treated for lung cancer with immune checkpoint inhibitors. Now, a new study published in the Journal of Thoracic Oncology found that vaccines are safe and effective for these patients. JTO is the official journal of the International Association for the Study of Lung Cancer.”

New Study Highlights Progress in Drug Development Landscape for Lung Cancer
“LUNGevity Foundation, the nation’s leading lung cancer-focused nonprofit organization, conducted a study analyzing the current global lung cancer drug development landscape. The manuscript, which was recently published in the Journal of Thoracic Oncology, reveals the impressive progress that has been made in the lung cancer therapy space and points to an increased need for comprehensive biomarker testing at earlier stages of the disease.”

ASCO: Merck touts Keytruda’s ‘convergent’ benefits across postsurgery lung cancer patient groups
“As biopharma industry watchers wait to see whether Keytruda will hit its goal as a postsurgery treatment in early lung cancer patients with high tumor expressions of the PD-L1 biomarker, Merck & Co. is rolling out new data to show the drug’s benefits across other patient groups.”

How Does Targeted Therapy Treat Lung Cancer?
“Targeted therapy is one of several new scientific approaches to treating cancers, including lung cancer. Doctors may recommend this approach if your lung cancer cells have certain targets that medications can work on. You can think of targeted therapies like specialized magnets drawn to cancer cells that will ignore healthy cells.”

Chemoimmunotherapy Shows 3-Year Survival Benefit for Advanced NSCLC
“During a live virtual event, Adam J. Schoenfeld, MD, discussed the updated 3-year results of the CheckMate 9LA trial of nivolumab, ipilimumab, and 2 cycles of chemotherapy for patients with advanced non–small cell lung cancer.”

Rates of advanced lung cancer decline after low-dose CT guidelines, cost coverage
CHICAGO — “Analysis of the SEER database showed a significant decline of rates of advanced lung cancer following screening guidelines for low-dose chest computed tomography.”

Are New Therapeutic Options for Limited-Stage SCLC Coming Down the Turnpike?
“Despite some recent wins in treatments for small-cell lung cancer (SCLC), the standard of care for limited-stage SCLC (LS-SCLC) “has not appreciably shifted in more than 20 years,” according to one expert group.”

VIDEO: Integrating sequential immunotherapy to lung cancer treatment plans
“In this video, Melina Marmarelis, MD, highlights findings from a Lung-MAP nonmatched substudy presented at ASCO Annual Meeting.”